Physician profile
Marshall Logan
NPI 1699231019
$2,151.22
in general payments reported to CMS, 2019-2025
12 companies · $2,151 in 2025
The $2,151 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053 · Education: $98.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.87 |
| Education | $98.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $301.95 | 2025 | Dupixent |
| Incyte Corporation | $283.66 | 2025 | Opzelura, Opzelura |
| Ucb, INC. | $243.32 | 2025 | Bimzelx |
| Leo Pharma INC. | $213.35 | 2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $193.00 | 2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $180.06 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $174.94 | 2025 | Zoryve |
| Botanix Sb INC | $153.37 | 2025 | Sofdra |
| Genzyme Corporation | $132.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $127.88 | 2025 | |
| Abbvie INC. | $74.50 | 2025 | |
| Pfizer INC. | $73.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Logan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.